COVID-19：美国的创新者Kaneka将疫苗生产外包：用于治疗的DNA药物
[路透社12月3日]
Innobio制药：
12月3日，Innovio宣布已同意将新的冠状病毒疫苗的生产外包给Kaneka。
该协议将在Innovio和Kaneka Eurogentech之间签署。
条件尚未公布。
Innovio已经与Thermo Fisher Scientific达成协议，将疫苗生产外包。
Innovio Corona疫苗：
Innobio的电晕疫苗目前正在某些3期临床试验中。
FDA需要有关疫苗接种期间使用的设备的更多信息。
路透社
https://jp.reuters.com/article/health-coronavirus-inovio-pharma-idJPKBN28D2BN
Inovio Pharmaceuticals, Inc. – INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
PLYMOUTH MEETING, Pa.,
Dec. 3, 2020 /PRNewswire/
INOVIO (NASDAQ:INO), a biotechnology company
focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer,
today announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation,
for Eurogentec to manufacture INOVIO’s COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales.
Terms of the agreement were not disclosed.
Kaneka Eurogentec
joins existing partners
Thermo Fisher Scientific,
Richter-Helm BioLogics and
Ology Biosciences
in INOVIO’s global manufacturing consortium.
Each contract development and manufacturing organization that has been selected to join the consortium is compliant with commercial GMP standards and capable of supporting INOVIO’s future large-scale global manufacturing needs across its portfolio of DNA medicines and vaccines